Non-traditional cardiovascular disease risk factors in end-stage renal disease: Oxidate stress and hyperhomocysteinemia

Current Opinion in Nephrology and Hypertension

Volumn 9, Issue 5, 2000, Pages 477-487

  Kitiyakara, Chagriya ^a   Gonin, Joyce ^a   Massy, Ziad ^b   Wilcox, Christopher S ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMINOGUANIDINE; ASCORBIC ACID; FOLIC ACID; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTIFICIAL KIDNEY; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DIET SUPPLEMENTATION; GLYCATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY FAILURE; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; VITAMIN DEFICIENCY;

CARDIOVASCULAR DISEASES; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, LDL; OXIDATIVE STRESS; RISK FACTORS; UREMIA;

EID: 0033849832     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200009000-00004     Document Type: Review

References (105)

1. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease
2. Serum malodialdehyde and prevalent cardiovascular disease in hemodialysis
3. Antioxidants for hypertension
4. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of carbonyl stress in long-term uremic complications
5. Amadorins: Novel post-amadori inhibitors of advanced glycation reactions
6. Advanced glycation end products: A nephrologist's perspective
7. Is oxidized low density lipoprotein present in vivo?
8. Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis
9. Biomarkers of free radical damage applications in experimental animals and in humans
10. Critical evaluation of plasma and LDL oxidant trapping potential in hemodialysis patients
11. Oxidized phospholipids and isoprostanes in atherosclerosis
12. Oxidative stress in chronic renal failure
13. Pathophysiology of the oxidative stress and its implication in uremia and dialysis
14. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors
15. Detection of oxidants in uremic plasma by electron spin resonance spectroscopy
16. Nature and biological significance of free radicals generated during bicarbonate hemodialysis
17. Recombinant human erythropoietin enhances superoxide production by FMLP-stimulated polymorphonuclear leukocytes in hemodialysis patients
18. Vitamin E alleviates the oxidative stress of erythropoietin in uremic children on hemodialysis
19. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis
20. Endothelial function in hypertension
21. Interactions between NO and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure
22. Advanced oxidation protein products as a novel marker of oxidative stress in uremia
23. Elevated plasma protein 3-chlorotyrosine (3-TC) in chronic hemodialysis patients-a marker of myeloperoxidase(MPO) catalyzed oxidant stress
24. Immunological evidence for hypochlorite-modified proteins in human kidney
25. The effects of dialyser reuse on plasma antioxidative mechanisms in patients on regular hemodialysis treatment
26. Lack of oxidative damage in serum polysaturated fatty acids before and after dialysis in chronic uremic patients
27. Plasma concentrations of vitamin C, vitamin E and/or malodialdehyde as markers of oxygen free radical production during hemodialysis
28. Thiobarbituric acid reactive substances are increased in the subcutaneous fat tissue of patients with end-stage renal disease
29. Auto antibodies against oxidatively-modified LDL in uremic patients underdoing dialysis
30. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure
31. Enhanced LDL oxidation in uremic patients: Additional mechanism for accelerated atherosclerosis?
32. Oxidation of low density lipoprotein in hemodialysis patients: Effect of dialysis and comparison with matched controls
33. Discrepancies between serum and erythrocyte concentrations of vitamin E in hemodialysis patients role of HDL-bound fraction of vitamin E
34. Low levels of dehydroacorbic acid in uraemic serum and the partial correction of dehydroascorbic acid deficiency by hemodialysis
35. Factors influencing oxidative stress in hemodialysis patients
36. Higher levels of antioxidant defenses in Enalaphril-treated versus non-Enalaphril-treated hemodialysis patients
37. Decrease in paraoxonase activity in chronic renal failure
38. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures
39. Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood-relevance to atherogenesis caused by hemodialysis
40. Oxidative stress and gene regulation
41. Antioxidants and atherosclerotic heart disease
42. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo
43. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: Role of nitric oxide
44. 2
45. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension
46. Enhanced scavenger receptor expression in monocyte-macrophages in dailysis patients
47. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease
48. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure
49. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study
50. Vitamin E and heart disease: Basic science to clinical intervention trials
51. Gruppo Italiano per to Studio della Sopravvivenza nell'Infarto Miocardico
52. Vitamin E supplementation and cardiovascular events in high-risk patients
53. Hemodialysis impairs endothelial function via oxidative stress: Effects of vitamin E-coated dialyzer
54. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients
55. Elevation of whole-blood glutathione in peritoneal dialysis patients by L-2-oxothiazolidine-4-carboxylate, a cysteine prodrug (Procysteine®)
56. Increased red blood cell survival reduces the need of erythropoietin in hemodialyzed patients treated with exogenous glutathione and vitamin E-modified membrane
57. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency
58. Reduction of plasma apolipeprotein-B by effective removal of circulating glycation derivatives in uremia
59. Pharmacological modulation of AGEs: A unique role for redox-active metal ions
60. Pimagedine (PG) lowers total urinary protein (TUP) and slows progression of overt diabetic nephropathy in patient with type 1 diabetes mellitus (DM)
61. 2-Isopropylidenehydrazono-4-oxothiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: Role of glycoxidation and lipoxidation reactions in vascular tissue damage
62. Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress
63. Low-density lipoprotein-independent effects of statins
64. Background and rationale behind the SU.VI.MAX Study, A prevention trial using nutritional doses of a combination of antioxidant and minerals to reduce cardiovascular diseases and cancers
65. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience
66. The metabolism of homocysteine: Pathways and regulation
67. Determination of reduced and oxidized homocysteine and related thiols in plasma by thiol-specific pre-column derivatization and capillary electrophoresis with laser-induced fluorescence detection
68. Detection of total homocysteine in plasma, serum and urine by automated fluorescence polarization immunoassay
69. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration
70. Renal uptake and excretion of homocysteine in rats with acute hyperhomocysteinemia
71. No net renal extraction of homocysteine in fasting humans
72. Homocysteine and methionine metabolism in ESRD: A stable isotope study
73. Evidence of altered homomcysteine metabolism in chronic renal failure
74. Effects of high-dose folic acid and pyridoxine on plasma and erythrocyte sulfur amino acids in hemodialysis patients
75. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients
76. Blood levels of homocysteine and increased risks of cardiovascular disease
77. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians
78. 6 and risk of myocardial infarction in US physicians
79. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial
80. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study
81. Serum total homocysteine and coronary heart disease
82. Plasma homocysteine levels and morality in patients with coronary artery disease
83. Elevated fasting total plasma homocysteine levels and cardiovascular risk factor in end-stage renal disease
84. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
85. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study
86. Homocysteine provokes leukocyte-endothelium interaction by downregulation of nitric oxide
87. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine
88. The role of oxidative stress in atherosclerosis: The hope and the hype
89. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans
90. Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilatation in humans
91. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
92. Metabolic consequences of folate-induced reduction of hyperhomocystein-emia in uremia
93. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy
94. Plasma folate conjugase activities and folate concentrations in patients receiving hemodialysis
95. Homocysteine and atherothrombosis
96. Intestinal absorption of 5-methyltetrahydrofolate in experimental uremia
97. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease
98. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients
99. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients
100. Folic acid treatment of hyperhomocysteinemia in dialysis patients
101. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure
102. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease
103. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study
104. Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation